The table below provides an overview of the recommendations by category, federal actions to address the recommendations, and funding and status for each action. The details of the implementation status for each recommendation is detailed in the following pages.
Vanderbilt University Medical Center Reporter. Study tracks impact of NAS on state Medicaid programs. (2018, March 23). Retrieved March 29, 2018, from https://news.vanderbilt.edu/2018/03/23/study-tracks-impact-of-nas-on-state-medicaid-programs .
Agency for Healthcare Research and Quality Kamila Mistry Administration for Children and Families Elaine Stedt Jean Blankenship Centers for Disease Control and Prevention Alex Ewling Jean Ko Jennifer Lind Lisa Romero -- Subgroup Lead: Data and Surveillance Meghan Frey Centers for Medicare & Medicaid Services K
Status Report on Protecting Our Infants Act Implementation Plan. APPENDIX A. BHCC Opioid and Controlled Substances Subcommittee Members
Administration for Community Living Keri Lipperini Phantane Sprowls Shannon Skowronski Agency for Healthcare Research and Quality Parivash Jourjah Richard Ricciardi Centers for Disease Control and Prevention Farida Ahmad Holly Hedegaard LeShaundra Cordier Margaret Warner Rose Rudd Sarah Bacon Tamara Haegerich
Status Report on Protecting Our Infants Act Implementation Plan. Recommendations Addressing Research and Evaluation Changes
Recommendations addressed by the following agencies: 29. Determine the safety and effectiveness of naltrexone and naloxone when combined with buprenorphine use during pregnancy and breastfeeding. (Research & Evaluation, Maternal) NICHD, NIDA, SAMHSA 30. Research consequences of unrelieved pain on women and their pregnancies. (Res
Status Report on Protecting Our Infants Act Implementation Plan. Recommendations Addressing Data and Surveillance Changes
Recommendations addressed by the following agencies: 24. Standardize terminology and promote a unified approach to data collection and reporting in order to accurately quantify prenatal substance exposure and identify risk and protective factors amenable to preventive efforts. (Data & Surveillance, Child)
Status Report on Protecting Our Infants Act Implementation Plan. Recommendations Addressing Clinical Changes
Recommendations addressed by the following agencies: 17. Improve and expand screening to identify women in need of brief intervention, and referral to treatment. (Data & Surveillance, Maternal) ACF/Children's Bureau, AHRQ, CDC, CMS, HRSA, IHS, NIDA, OASH/OWH, SAMHSA 18. Define and understand the elements of an effective risk-bene
Status Report on Protecting Our Infants Act Implementation Plan. Recommendations Addressing Systemic Changes
Recommendations addressed by the following agencies: 1. Increase access to the broad range of contraceptive options for women at risk of experiencing a substance-exposed pregnancy, including barrier free access to long-acting reversible contraception. (Programs & Services, Maternal) CDC, CMS, HRSA, IHS
Status Report on Protecting Our Infants Act Implementation Plan. SUSTAINING HHS POIA IMPLEMENTATION PLAN EFFORTS
After the final implementation plan is approved, the BHCC Opioid and Controlled Substances Subcommittee will assume responsibility for the ongoing implementation and coordination of NAS and prenatal opioid exposure related activities to assess progress, evaluate effectiveness, and publicize NAS-specific programs and tools, contingent on funding.
All POIA recommendations are being addressed by HHS, with the majority of recommendations being addressed through dedicated cross-agency collaboration.
Status Report on Protecting Our Infants Act Implementation Plan. IMPLEMENTATION PLAN PURPOSE AND DEVELOPMENT PROCESS
In recognition of the need for an organizing framework to guide and track implementation of recommendations in the POIA Strategy, the HHS Behavioral Health Coordinating Council (BHCC) Opioid and Controlled Substances Subcommittee, NAS Workgroup developed this implementation work plan. This plan provides an update on the POIA implementation plan ac
A new study revealed that from 2004 to 2014, the rate of US infants diagnosed with opioid withdrawal symptoms increased 433%, from 1.5 to 8.0 per 1000 hospital births. This translates to one infant being born every 15 minutes with withdrawal symptoms due to prenatal opioid exposure. [ 1 ], [ 2 ]
AAP American Academy of Pediatrics ACF Administration for Children and Families ACT NOW Advancing Clinical Trials for Neonatal Opioid Withdrawal ACYF Administration on Children, Youth and Families
Substance Abuse and Mental Health Services Administration January 17, 2019 Printer Friendly Version in PDF Format (109 PDF pages)
The Protecting Our Infants Act of 2015 (POIA) became law on November 25, 2015. The Act (Public Law 114-91) addressed problems related to prenatal opioid exposure called for HHS to review planning and coordination of HHS activities related to prenatal opioid exposure and neonatal abstinence syndrome (NAS), and to study and develop recommendations f
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX F: National Drug Codes Used to Identify Prescription Drug Fills for Substance Use Disorders in Preliminary Analysis
National Drug Code Product Name Use Dosage in MG 00456-3330-01 CAMPRAL AUD 333
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX E: Supplemental Regression Analyses Results
Annual Descriptive Trends and Simple Regression Analysis We produced annual outcome trends for the average and 95thpercentile for all service categories, comparing non-BH, MH, and SUD diagnosis groups as well as OUD and non-OUD SUD trends. We then produced plotted graphs to visually assess whether there were distinct patterns in results or disco
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX D: Prescription Drug National Drug Codes Used to Identify Opioid Use Disorder Subpopulation
NDC Prod_Name Route of Admin Master Form Code Strength in MG Generic Name
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX C: Mental Health and Substance Use Disorder Diagnosis Codes
ICD-9-CM Diagnosis Code Description of ICD-9-CM Diagnosis Code MH or SUD Diagnosis Group Related CCS Category 3090 Adjustment disorder with depressed mood